-
Mashup Score: 0European Commission Approves Glofitamab in Relapsed/Refractory DLBCL - 10 month(s) ago
Results from the phase 1/2 NP30179 trial led the European Commission to grant conditional marketing authorization to patients with relapsed/refractory diffuse large B-cell lymphoma.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Adagrasib Demonstrates Intracranial Activity in KRAS G12C+ NSCLC - 10 month(s) ago
Findings from the phase 1b KRYSTAL-1 trial support the continued development of adagrasib in the treatment of patients with KRAS G12C–mutated non–small cell lung cancer and central nervous system metastases.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Hypersensitivity reactions following platinum-based treatment appear to be more severe than hypersensitivity reactions after taxanes among patients with cancer.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Pembrolizumab/Chemo Extends PFS In Advanced/Recurrent Endometrial Cancer - 10 month(s) ago
Pembrolizumab plus chemotherapy may improve clinical outcomes over placebo among patients with advanced or recurrent endometrial cancer.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Cohort Study Identifies Factors Independently Associated With Breast Cancer–Related Lymphedema Risk Post-ALND - 10 month(s) ago
After identifying several factors independently associated with the risk of breast cancer–related lymphedema following axillary lymph node dissection, investigators recommend further studies to examine biologic mechanisms behind racial and ethnic disparities within this space.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Unmet Needs and Future Perspectives in Newly-Diagnosed and Relapsed Multiple Myeloma - 10 month(s) ago
Closing out their discussion, the panel shares remaining unmet needs in the treatment of newly-diagnosed and relapsed multiple myeloma.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0European Commission Approves Glofitamab in Relapsed/Refractory DLBCL - 10 month(s) ago
Results from the phase 1/2 NP30179 trial led the European Commission to grant conditional marketing authorization to patients with relapsed/refractory diffuse large B-cell lymphoma.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Docetaxel does not appear to yield meaningful absolute improvements in survival among patients with metastatic castration-sensitive prostate cancer with low-volume, metachronous disease.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Diagnosing Bladder Cancer: Best Practices in Workup and Staging - 10 month(s) ago
Shared insight on the standard work-up and staging practices used when a patient presents with newly diagnosed bladder cancer.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Application of Bispecific Therapy in Clinical Practice - 10 month(s) ago
Syed S. Ali, MD, and Noffar Bar, MD, share their practical experience with bispecific antibodies in the treatment of patients with multiple myeloma.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
The European Commission has granted conditional marketing authorization for glofitamab-gxbm to be used in patients with relapsed/refractory diffuse large B-cell lymphoma after 2 or more lines of therapy. #lymsm | @EU_Commission https://t.co/yah0TrPG8I